- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Ondine Biomedical - Ondine and Mid Yorks Win National Award | - | RNS | ||
| Mo | Ondine Biomedical - Steriwave Up for 2025 "Product of the Year" Award | - | RNS | ||
| 27.01. | Ondine Biomedical: Kanadisches Krankenhaus führt Steriwave zur Infektionsprävention ein | 4 | Investing.com Deutsch | ||
| ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 27.01. | Ondine Biomedical - Expanding Steriwave Use Across Vancouver Island | 2 | RNS | ||
| 22.01. | Ondine Biomedical - Steriwave Expands into ENT Surgery in Spain | 2 | RNS | ||
| 13.01. | Ondine Biomedical - New Independent Study Supports Photodisinfection | - | RNS | ||
| 23.12.25 | Ondine Biomedical - Finalist for 2nd National Award for SSI reduction | - | RNS | ||
| 22.12.25 | Ondine Biomedical - First German Hospital Pilots Steriwave | - | RNS | ||
| 16.12.25 | Ondine Biomedical - Ondine shortlisted for HSJ Partnership Award | - | RNS | ||
| 27.10.25 | Ondine Biomedical - Topline Results Significant in Steriwave ICU Study | 4 | RNS | ||
| 02.10.25 | Ondine Biomedical - Cambridge's Papworth Hospital Pilots Steriwave | 1 | RNS | ||
| 26.09.25 | UK Stock Market News: Pennon, Seeing Machines, Ondine | 6 | The Armchair Trader | ||
| 26.09.25 | Ondine Biomedical - Ondine Biomedical Continues Growth in H1 2025 | 1 | RNS | ||
| 23.09.25 | Ondine Biomedical - Steriwave Now Protecting Patients with Cancer | - | RNS | ||
| 19.09.25 | Ondine Biomedical - Notice of Interim Results & Investor Presentation | - | RNS | ||
| 18.09.25 | Ondine reports 70% reduction in surgical site infections with Steriwave | 2 | Investing.com | ||
| 18.09.25 | Ondine: Steriwave senkt postoperative Wundinfektionen um 70 % | 2 | Investing.com Deutsch | ||
| 18.09.25 | Ondine Biomedical - Ondine Presents Major Economic Benefits at ICPIC | - | RNS | ||
| 15.09.25 | Ondine Biomedical - Steriwave proven to be effective against C Auris | - | RNS | ||
| 12.09.25 | Ondine Biomedical - Grant of Options | - | RNS |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,360 | +1,40 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ONDINE BIOMEDICAL INC CDIS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +15,56 % bei einem Aktienkurs von 0,078 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONDINE BIOMEDICAL INC CDIS finden Sie auf Wallstreet Online.